Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Data Validation01:15

Data Validation

579
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
579
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Treatments for Migraine-Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe.

JAMA internal medicine·2021
Same author

Raising Medicaid Rebates For Drugs With Accelerated Approval.

Health affairs (Project Hope)·2021
Same author

Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.

JAMA internal medicine·2021
Same author

How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?

AMA journal of ethics·2021
Same author

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic.

Journal of general internal medicine·2021
Same author

Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe.

Nature reviews. Clinical oncology·2021

Related Experiment Video

Updated: Jan 19, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K

Challenges and Opportunities for Biomarker Validation.

Spencer Phillips Hey1, Elvira D'Andrea1, Emily H Jung1

  • 1Spencer Phillips Hey, Ph.D., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. He is also affiliated with the Center for Bioethics at Harvard Medical School. Elvira D'Andrea, M.D., M.P.H., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. Emily H. Jung, A.B., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. Frazer Tessema, B.A., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. Jing Luo, M.D., M.P.H., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. Bishal Gyawali, M.D., Ph.D., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. Aaron S. Kesselheim, M.D., J.D., M.P.H., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, at Harvard Medical School, in Boston, Massachusetts. He is also affiliated with the Center for Bioethics at Harvard Medical School, and serves as the Edited-in-Chief of the Journal of Law, Medicine & Ethics.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|September 28, 2019
PubMed
Summary

Biomarker validation is crucial for reliable diagnosis and treatment. New research initiatives are making the necessary data more accessible, simplifying this essential process.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Related Experiment Videos

Last Updated: Jan 19, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Area of Science:

  • Biomarker research and development
  • Clinical validation methodologies

Background:

  • Biomarkers are essential tools in medical diagnosis, treatment selection, and scientific research.
  • Formal validation is critical for the responsible application of biomarkers.
  • Historically, accessing data for biomarker validation has presented significant challenges.

Discussion:

  • Discusses the critical need for rigorous biomarker validation in clinical practice.
  • Highlights the traditional difficulties in obtaining necessary data for validation studies.
  • Emphasizes the role of new research initiatives in overcoming data access barriers.

Key Insights:

  • Biomarker utility is contingent upon robust validation.
  • Data accessibility is a primary bottleneck in biomarker validation.
  • Emerging research efforts are actively addressing data access challenges.

Outlook:

  • Future biomarker applications will increasingly rely on validated tools.
  • Continued development of data-sharing platforms and collaborative research is anticipated.
  • Streamlined validation processes will accelerate biomarker translation into clinical practice.